Circulating Tumor DNA (ctDNA) for Early Treatment Response Assessment of Solid Tumors
Recruiting
Observational Study
Healthy Volunteer
Prostate Cancer
Head and Neck Cancer
Esophageal Cancer
Genitourinary Cancer
Sarcoma
Breast Cancer
Colon Cancer
Gastrointestinal Cancer
Solid Tumor Cancer
Lung Cancer
Skin Cancer
Melanoma
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Healthy Volunteers Welcome
You do not need to have the condition being studied to take part.
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Study type
- Observational
- Participants needed
- 100 (estimated)
- Sponsor
- Washington University School of Medicine · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
Earlier detection of disease recurrence will enable greater treatment options and has strong potential to improve patient outcomes. This project is translational and has the potential to lead to future translational research opportunities, including interventional trials in which therapeutic escalation is offered at the early circulating tumor DNA (ctDNA) molecular residual disease (MRD) detection…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Eligible healthy donors will be at least 18 years of age.
Exclusion Criteria:
* Healthy donors younger than 18 years of age
Contacts